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ABSTRACT
ENHANCED RENAL SYMPATHETIC 
AND CARDIOVASCULAR RESPONSES 
TO SUBSTANCE P IN HYPERTENSION
by
Gregory W. Lindsay
Blood pressure, heart rate, and renal sympathetic nerve 
responses were measured in 9-13 week old male spontaneously 
hypertensive rats (SHR) and compared to those in age and 
sex-matched Wistar-Kyoto (WHY) rats following intravenous 
injection of the neuropeptide substance P (SP), the 
nicotinic stimulant 1,l-dimethyl-4-phenylpiperazinium 
(DMPP), and the adrenoceptor stimulant norepinephrine (NE). 
Charles River Sprague-Dawley (CD) rats were used in some 
studies to develop methodologies. Measurements were made in 
control rats and also following sinoaortic denervation, 
pithing, ganglion blockade, or adrenoceptor blockade.
Responses were evaluated in order to determine if 
ganglion stimulation by SP was enhanced in SHR compared to 
WHY rats and if this enhancement was selective for SP or 
would also be exhibited to DMPP. NE was used to evaluate 
adrenergic sensitivity and to confirm the success of 
baroreceptor denervations,
SHR exhibited greater intrinsic sympathetic tone than 
WKY rats before and following ganglion blockade. Ganglion 
stimulation by SP and DMPP was only fully revealed following 
elimination of baroreceptor input. Results indicated that 
SP stimulates sympathetic ganglia to increase renal 
sympathetic nerve activity, heart rate and blood pressure in 
CD, SHR and WKY rats. This increase was enhanced in SHR 
compared to WKY rats in the absence of a similar enhancement 
of responses to DMPP. The action of SP to cause 
vasodilation was attenuated in SHR versus WKY rats which may 
augment its action as a pressor agent in SHR.
In conclusion, increases in blood pressure, heart rate 
and renal sympathetic nerve activity were selectively 
increased to SP in SHR versus WKY rats. This enhanced 
action of SP may contribute to the elevation of basal and/or 
evoked sympathetic discharge observed in this model of 
hypertension.
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CHAPTER 1 
Introduction
Substance £
Substance P (SP) is one of the oldest known peptide 
neurotransmitters (Otsuka and Konishi, 1983). It was 
originally isolated from equine brain and intestine and 
noted to have a hypotensive action that was not blocked by 
atropine when injected intravenously into anesthetized 
rabbits (von Euler and Gaddum, 1931). The proposal that SP 
may act as a neurotransmitter or neuromodulator came 
somewhat later (Lembeck, 1953). The peptide is now known to 
be distributed throughout the central nervous system (Cooper 
et al., 1981) and is also found in several locations within 
the peripheral nervous system where it has a variety of 
functions (Schultzberg, 1983).
The presence of SP in the peripheral sympathetic 
nervous system was first shown by Pernow (1953). SP was 
later localized to nerve terminals surrounding principal 
cells of sympathetic ganglia by Hdkfelt and colleagues 
(1977). Several lines of evidence now indicate that SP is 
released in sympathetic ganglia where it acts to enhance 
neurotransmission by evoking a late-onset slow-excitatory 
postsynaptic potential (EPSP) (Otsuka and Yoshioka, 1993).
1
2Substance P in Hypertension
An enhancement of neurotransmission through sympathetic 
ganglia has been proposed to contribute to the development 
and/or maintenance of hypertension in spontaneously 
hypertensive rats (SHR) (Magee and Schofield, 1992). Since 
sympathetic ganglia of SHR have been shown to exhibit 
increased immunoreactivity to SP compared to normotensive 
Wistar-Kyoto (WKY) rats (Gurusinghe and Bell, 1989), SP may 
be involved in the pathogenesis of hypertension in this 
model. This proposal was tested in the current study by 
evaluation of blood pressure, heart rate and renal 
sympathetic nerve activity (RSNA) following intravenous 
injection of SP in SHR and WKY rats. The rationale for 
employing this methodology is based on studies which have 
shown that when given intravenously in sufficient doses (>1.0 
nmol/kg), SP has an action to increase blood pressure and 
heart rate which overcomes its hypotensive effect. These 
actions were prevented by adrenoceptor blockade or depletion 
of catecholamines with reserpine but not by ganglion nicotinic 
receptor blockade or pithing, therefore they appear to be due 
to stimulation of sympathetic ganglia (Hancock, 1992).
The hypothesis of the present study is that increases in 
blood pressure, heart rate, and RSNA observed after 
intravenous injection of SP will be greater in SHR than in WKY 
rats. Additionally, the increased responsiveness of SHR is 
proposed to be selective for SP and not be exhibited to other 
ganglion stimulants.
Overview of Hypertension
Circulatory diseases account for approximately one half 
of all deaths of people 50 years of age and older living in 
western countries, with the prevalence of hypertension in 
this population being about 55% (Kaplan, 1990; Whelton and 
Klag, 1989). Of particular significance is that the level 
of blood pressure serves as an accurate risk predictor for 
other circulatory disorders with high rates of mortality 
including coronary artery disease, cerebrovascular disease, 
and congestive heart failure. As a result, there has been 
abundant research directed at ascertaining possible causes 
and potential treatments for hypertension. Although current 
theories attempting to describe the pathogenesis remain 
varied and fraught with controversy, some factors have been 
identified which are likely to be involved in the etiology 
(Folkow, 1982).
Blood pressure is ultimately determined by the product 
of cardiac output and peripheral vascular resistance. 
Hypertension must therefore be the result of an increase in 
one or both of these factors. Studies indicate that both an 
enhanced cardiac output and increased vasomotor tone 
contribute to the pathogenesis of hypertension, but somewhat 
differently. Early hypertension is often characterized by 
an elevation in cardiac output with normal or even decreased 
resistance, while an increase in peripheral vascular 
resistance is generally considered to be the primary 
hemodynamic abnormality in established hypertension (Folkow,
41982). Both of these variables are controlled via 
Interaction of a variety of physiologic mechanisms. Among 
the most prominent and powerful of these is the sympathetic 
nervous system.
Importance of the Sympathetic Nervous System
The role of the sympathetic nervous system in 
initiating rapid cardiovascular adjustments to acute changes 
in the environment is well known. Following sympathetic 
stimulation, neurally released norepinephrine produces 
sustained arteriolar constriction in several vascular beds 
thus increasing peripheral vascular resistance. Sympathetic 
output to the heart and adrenal medulla causes both heart 
rate and stroke volume to increase, enhancing cardiac 
output. Sympathetic stimulation of the kidneys causes 
sodium and water retention with increased renin-angiotensin 
and aldosterone release, enhancing both cardiac output and 
vascular resistance. In this way, blood pressure is 
maintained or altered appropriately in order to accommodate 
the immediate and short term needs of an individual.
The role of the sympathetic nervous system in causing 
more or less permanent circulatory changes is less clear. 
Because the sympathetic nervous system regulates blood 
pressure via feedback mechanisms (i.e. input affects output 
and vice-versa), permanent changes in the physiological 
state of the heart and/or vasculature can result in chronic 
changes in sympathetic tone. In the same way, a persistent
5change in the output of sympathetic nerves can cause 
adaptive alteration of the cardiovascular system. Lastly, 
the neuronal circuitry may be disrupted, requiring more or 
less input for the same amount of output. In fact, each of 
these types of changes have been observed in hypertension 
(Abboud, 1982). It is therefore not surprising that the 
observation of enhanced basal and evoked sympathetic 
discharge in both human and experimental hypertension has 
received considerable attention (Folkow, 1989).
Structural Remodeling
Cardiovascular adaptations following chronic elevation 
of systemic arterial pressure occur in proportion to the 
level of hypertension and without regard to the cause.
Rapid structural alterations including hypertrophy of the 
heart and precapillary vessels are exhibited following 
sustained increases in intraluminal pressure (Folkow, 1978). 
This results in an increase in the ratio between wall 
thickness and lumen diameter that leads to the development 
of higher pressures in response to stimulation, an effect 
which has been proposed to be responsible for maintenance of 
chronic hypertension (Folkow, 1987). Decreased 
responsiveness to depressor substances is also observed, 
particularly those responses mediated by the vascular 
endothelium (Luscher et al., 1992).
However, cardiovascular remodeling may also occur 
independent of hypertension per se. There is considerable
evidence that sympathetic nerves have a trophic influence on 
vascular smooth muscles cells (Abel and Hermsmeyer, 1981}.
An increase in the vascular wall:lumen ratio has been 
observed in early hypertension which is dependent on the 
presence of sympathetic nerves (Hart et al., 1980), This is 
due to an increase in the mass of the medial layer of the 
vessel wall resulting from a hyperplasia and hypertrophy of 
vascular smooth muscle cells. This proliferation of smooth 
muscle cells can be demonstrated in cell culture upon 
addition of norepinephrine (Blaes and Boissel, 1983). In 
addition, surgical or chemical denervation of sympathetic 
nerves prevents vascular hyperplastic changes in 
experimental hypertension (Head, 1989). Thus, the 
sympathetic nervous system appears to mediate both acute and 
chronic increases in vascular resistance, and may be 
involved in the maintenance of chronic hypertension by this 
mechanism.
In addition to contributing to maintenance of chronic 
high blood pressure, increased sympathetic outflow is 
probably also an important factor during the developmental 
phase of hypertension. Sympathetic hyperresponsiveness to 
environmental factors such as emotional stress or increased 
dietary salt intake is often exhibited in individuals 
genetically predisposed to hypertension (Folkow, 1989). In 
particular, sympathoadrenal responsiveness is often elevated 
(de Champlain et al., 1989), resulting in increased release 
of epinephrine and perhaps contributing to the increase in
cardiac output often observed in early hypertension. A 
possible explanation for this hyperresponsiveness is an 
alteration in nervous control of sympathetic tone.
Neurogenic Control 
Sympathetic neurons involved in regulation of the 
cardiovascular system may be classified on the basis of 
function as those associated with the origination of 
sympathetic discharge, those involved only in modulation of 
sympathetic tone, and those which integrate and deliver 
sympathetic discharge to target organs.
A. Generation of Sympathetic outflow 
Sympathetic discharge to the cardiovascular system is 
believed to be generated by spontaneous activity present 
within cells of the rostral ventrolateral medulla (RVLM). 
Specifically, epinephrine-containing cells of the Cl 
(catecholamine) area of the RVLM appear to provide tonic 
excitatory input to sympathetic preganglionic neurons in the 
intermediolateral (IML) cell column of the spinal cord (Reis 
et al., 1988). This hypothesis is supported by the fact 
that destruction or inhibition of Cl neurons markedly 
depresses sympathetic tone resulting in hypotension and 
bradycardia, m  addition, increases in arterial pressure 
are observed following stimulation of medullary sites 
containing descending Cl axons (Calaresu and Yardley, 1988). 
In conflict with this hypothesis is the observation
8that application of epinephrine to the IML cell column 
consistently inhibits firing of preganglionic nerves, an 
effect which is blocked by e2-adrenoceptor antagonists 
(Guyenet and stornetta, 1982). This suggests that 
bulbospinal epinephrine pathways are not excitatory but may 
be Bympathoinhibitory in nature. In addition, while ct2 
antagonists appear to block all the effects of epinephrine 
on sympathetic preganglionic neurons, they fail to prevent 
excitation of preganglionic cells elicited by stimulation of 
pressor sites in the Cl area of the RVIM (McCall, 1990). 
Therefore, although the generation of sympathetic tone is 
likely to be mediated by cells within or in close proximity 
to Cl neurons, they do not appear to utilize epinephrine as 
their sole transmitter. Other neurotransmitters of the RVLM 
which may play a role in maintaining vasomotor tone include 
glutamate, 5-hydroxytryptamine (5-HT), and the neuropeptide 
substance P (SP) (McCall, 1990).
B. Modulation of Sympathetic Tone 
Basal sympathetic tone is modified by several inputs at 
virtually all levels. This myriad of inputs allows for 
exceptional selective control of sympathetic discharge. It 
also creates numerous opportunities for potential 
disturbances in neuroregulation and great difficulty in 
pinpointing the origin of these disturbances. Supraspinal 
structures known to influence sympathetic tone include the 
nucleus tractus solitarius (NTS), caudal ventrolateral
medulla, circumventricular organs, basal forebraln, dorsal 
raphe nuclei, parabrachial nucleus, Al and A5 noradrenergic 
cell groups, several areas within the hypothalamus, and the 
cerebral cortex (McCall, 1990). Because abundant relays 
originating from several nuclei occur in the NTS, it serves 
as a kind of central processor, integrating input from the 
many other brain stem and forebrain nuclei and relaying it 
to the RVLM.
Neurons in the Cl area of the RVLM receive dense input 
from the NTS, which is in turn highly innervated by sensory 
fibers from arterial baroreceptors and other cardiopulmonary 
afferents (Brody, 1986). Baroreceptors are specialized 
nerve endings found in the carotid body and aortic arch 
which increase their rate of firing in response to 
distension of the arterial wall. Changes in blood pressure 
alter the strain on these fibers thus influencing their 
discharge rate. Increased baroreceptor activity excites 
neurons in the NTS which causes inhibition of 
sympathoexcitatory neurons in the RVm. This neuronal 
negative feedback helps to buffer against changes in 
arterial pressure. Alterations in the reflex may therefore 
contribute to chronic changes in arterial pressure. The 
observation that vascular compliance is decreased in 
hypertension lead to the hypothesis by some researchers that 
reduced baroreceptor stretch might cause chronic elevation 
of sympathetic tone. This was subsequently thought to be 
unlikely when it was determined that baroreceptors reset to
new thresholds following sustained Increases In arterial 
pressure (McCubbln et al., 1956). However, since 
baroreceptors resist changes In blood pressure, they may 
play a role in the maintenance of hypertension. Resetting 
of the reflex to a higher pressure threshold may actively 
oppose a subsequent return to normal blood pressure levels.
C. Delivery of Sympathetic Outflow 
Centrally generated sympathetic discharge is carried by 
a serially linked two-neuron pathway to effector cells in 
the periphery# constituting the final phase in sympathetic 
nervous control of the cardiovascular system. Nervous 
activity in descending tracts is transferred to 
preganglionic neurons in the IML cell column of the spinal 
cord which relay their output through sympathetic ganglia to 
postganglionic neurons innervating the target organs. 
However, this pathway is more than a simple relay circuit 
for transfer of information from higher centers to the 
periphery. Integration of information from a multitude of 
sensory and supraspinal inputs occurs, thus ensuring highly 
differentiated sympathetic output to multiple target cells.
sympathetic Preganglionic Neurons
A. Inputs
Preganglionic sympathetic neurons receive inputs from 
supraspinal neurons as well as visceral and somatic spinal 
afferents. Since visceral and somatic sensory fibers also
XI
influence descending input from supraspinal cell groups, 
afferent modulation of sympathetic tone at the level of the 
preganglionic neuron is extensive. This markedly influences 
not only the level of activity in sympathetic preganglionic 
neurons, but also their pattern of discharge.
B. Synchronized Discharge 
Ongoing activity in sympathetic nerves is usually 
synchronized in a periodic fashion either with pulse 
pressure or respiration, depending on the target organ 
(Laskey and Polosa, 1988). This rhythmicity is directly 
related to the strength of inhibitory influences exerted on 
sympathetic discharge by peripheral cardiopulmonary and 
baroreceptor inputs. These sensory fibers affect 
sympathetic tone via central pathways involving the NTS. 
However, it should be noted that rhythmic modulation of 
sympathetic activity has also been observed in baroreceptor 
denervated animals which is not synchronized with pulse 
pressure or respiration. This rhythmicity has been 
attributed to activity of supraspinal oscillators (Kenney et 
al., 1990; Barman et al, 1992). When arterial baroreceptors 
are intact these oscillators are thought to become entrained 
to the rhythm of afferent nerve activity. Whatever the 
case, afferent influences on sympathetic preganglionic nerve 
activity are considerable.
C. Electrophysiology
Four types of synaptic potentials have been identified 
in sympathetic preganglionic neurons in vitro. These are: a 
fast and a slow excitatory postsynaptic potential (EPSP) and 
a fast and a slow inhibitory postsynaptic potential (IPSP). 
Not all of these necessarily occur in every preganglionic 
cell (Simmons, 1985).
Stimulation of dorsal roots (sensory input to the spinal 
cord) elicits an excitatory synaptic potential in 
preganglionic neurons of long but variable length (2-10 ms) 
which is capable of producing an action potential (Tsunoo et 
al., 1982). This type of potential is classified as a fast 
EPSP. Because of the varying length, it probably represents 
events mediated by one or more interneurons. The response 
has been attributed to stimulation of N-methyl-D-aspartate 
(NMDA) receptors due to similarities in the evoked 
depolarizations and the fact that NMDA receptor antagonists 
block fast EPSP's following dorsal root stimulation (Dun et 
al., 1992). A non-NMDA mediated fast EPSP of shorter 
duration has also been noted. The transmitter(s) mediating 
this response remains unknown.
Fast IPSP's are noted in about 30% of preganglionic 
neurons following stimulation of the dorsal roots. This is 
blocked by the glycine antagonist strychnine, but not the 
gamma aminobutyric acid (GABA) antagonist bicuculline (Dun et 
al., 1992). Thus, inhibitory glycine interneurons probably 
mediate fast IPSP's in sympathetic preganglionic neurons.
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Studies using antagonists and/or putative transmitters 
indicate that the transmitter responsible for slow EPSP's in 
preganglionic neurons is heterogeneous. Some possible 
transmitters mediating this response include norepinephrine, 
epinephrine, substance p, 5-HT, glutamate, and vasopressin 
(Dun et al., 1991). Slow IPSP's are blocked by 0 2- 
adrenoceptor antagonists, and thus are likely to be mediated 
by catecholamines (Nishi, 1990).
Sympathetic Ganglia
A. Overview
It has become clear that preganglionic signals are not 
conveyed to postganglionic neurons by simple excitatory 
monosynaptic transmission. Neurotransmission in sympathetic 
ganglia involves a variety of synaptic events whereby 
central and peripheral inputs are integrated. Excluding 
presynaptic modulation of transmitter release occurring at 
the adrenergic nerve terminal, this constitutes the final 
point for adjustment of sympathetic discharge.
The neural elements which participate in ganglionic 
transmission are: preganglionic nerve terminals, post­
ganglionic neurons (which have their cell bodies in 
sympathetic ganglia), ganglionic interneurons (strongly 
immuno-fluorescent i.e. SIF cells), axons from post­
ganglionic cells in neighboring ganglia, and collaterals 
from visceral sensory fibers. Glial cells may also be 
present in some sympathetic ganglia participating in
14
modulation of transmission.
Classically, preganglionic nerve fibers projecting to 
sympathetic ganglia exert effects on postganglionic neurons 
via release of the neurotransmitter acetylcholine, which 
stimulates postjunctional nicotinic receptors. Recently, 
immunoreactivity to the peptides calcitonin gene related 
peptide (CGRP) and vasoactive intestinal peptide (VIP) has 
been demonstrated in preganglionic neurons projecting to the 
superior cervical ganglia of the rat (Yamamoto et al., 1989; 
Baldwin et al., 1991). These peptides may function either 
as neurotransmitters or as modulators of transmission in 
sympathetic ganglia.
B. Prejunctional Modulation
Prejunctional modulation of transmitter release occurs 
in sympathetic ganglia via several types of receptors. 
Activation of muscarinic acetylcholine receptors of the M2 
type found on the axon terminal has been shown to inhibit 
synaptic transmission. Adrenoceptors of the a2 type, 5-HTi 
receptors, histamine H2 receptors, and opiate receptors also 
appear to decrease transmitter release from the 
preganglionic nerve terminal. On the other hand, activation 
of B-adrenoceptors, histamine H2 receptors, VIP receptors, 
or angiotensin II receptors found on the preganglionic nerve 
terminal results in an enhancement of ganglionic 
neurotransmission. Inhibitory effects on neurotransmission 
due to the actions of GABA and prostaglandin E2 have also
15
been noted, however their mechanisms of action are unclear 
(Kuba and Minota, 1986).
C. Postsynaptic Responses
At least three types of excitatory receptors are found 
postsynaptically on sympathetic ganglion cells: nicotinic, 
muscarinic, and peptidergic. Stimulation of these receptors 
results in the generation of a fast EPSP, slow EPSP, and 
late slow EPSP, respectively (Elfvin et al., 1993).
Nicotinic and muscarinic receptor stimulation is due to 
acetylcholine released from the preganglionic nerve 
terminal. It has recently been determined that peptidergic 
stimulation results from the release of the neuropeptide SP 
from axon collaterals of primary sensory neurons of the 
dorsal root ganglia (Otsuka and Konishi, 1983). Similar 
ganglion stimulatory actions have also been attributed to 
other peptides such as calcitonin gene-related peptide 
(CGRP), which occurs with SP in some sensory fibers (Gibbins 
et al., 1985), but these effects are less well established. 
Circulating peptides with stimulatory effects on ganglionic 
transmission include angiotensin II and bradykinin, which 
may be important in hormonal modulation of sympathetic tone.
Inhibitory potentials in mammalian sympathetic ganglia 
are less well understood, although a slow IPSP can be 
demonstrated following nicotinic receptor blockade which may 
be due either to stimulation of muscarinic receptors, 
catecholamine receptors, or both (Elfvin et al., 1993).
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Muscarinic receptor mediated slow IPSPs are difficult to 
study due to superimposition of the muscarinic slow EPSP. 
Catecholamines in sympathetic ganglia might be released from 
SIF cells or from axons of neighboring ganglia.
Amplitudes of fast EPSPs are usually large enough to 
generate an action potential at the postsynaptic site, 
therefore nicotinic transmission is a primary synaptic 
pathway in sympathetic ganglia (Kuba and Minota et al.,
1986). However, visceral afferent control of sympathetic 
tone also appears to be significant. A delayed onset, long- 
lasting depolarization is produced following application of 
SP to sympathetic ganglion neurons (Dun and Karczmar, 1979) 
which has been shown to be capable of generating action 
potentials (Konishi and Otsuka, 1985). In addition, 
sympathetic activity is enhanced following intravenous 
injection of SP resulting in increases in blood pressure and 
heart rate (Hancock et al., in preparation), since SP- 
containing sensory nerve terminals innervate both the 
peripheral vasculature and sympathetic ganglia, this may 
provide a mechanism for peripheral reflex regulation of 
vasomotor tone.
The Spontaneously Hypertensive Rat
Studies directed at defining the role of the 
sympathetic nervous system in hypertension have often 
utilized the SHR, a genetic model in which hypertension 
develops gradually with age. As in human essential
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hypertension, this increase in blood pressure is very 
closely associated with increased activity of the 
sympathetic nervous system (Judy et al., 1976). Studies in 
the SHR utilize the inbred normotensive WKY rat as a 
control. WKY rats are similar in lineage to the SHR but do 
not develop hypertension (Louis and Howes, 1990).
Several points within both the central and peripheral 
sympathetic nervous system have been identified as possible 
locations for disturbances which affect regulation of 
sympathetic tone in the SHR (Ekas et al., 1981). Some 
factors which may potentially operate to increase 
postganglionic sympathetic tone include: an enhanced action 
of angiotensin at circumventricular organs (Brody et al., 
1991), attenuation of baroreceptor sensitivity (Nosaka and 
Wang, 1972), hypernoradrenergic innervation (Head, 1991), 
altered membrane handling of sodium (Folkow and Ely, 1987), 
and differences in modulation of sympathetic tone by 
sympathetic ganglia (Magee and Schofield, 1992). It is 
difficult to point to one causative factor since changes 
occurring peripherally can affect central control of 
sympathetic tone, and vice versa.
Of particular interest is the fact that neonatal 
depletion of sensory peptides by treatment with capsaicin 
prevents the development of hypertension in SHR (Scott and 
Pang, 1982). Since capsaicin selectively depletes sensory 
peptides, this indicates that sensory nerves play a role in 
the development of hypertension in the SHR. It is unknown
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if capsaicin treatment is accompanied by a decrease in 
sympathetic tone. However, this may be the case since the 
sensory peptide SP is known to significantly enhance 
neurotransmission in sympathetic ganglia (Konishi and 
Otsuka, 1985). In addition, observations that 
immunoreactivity to SP is increased in sympathetic ganglia 
of SHR (Gususinghe and Bell, 1989) support the idea that 
sensory nerves are involved in elevating sympathetic tone in 
SHR, perhaps contributing to the development and/or 
maintenance of hypertension. If sensory peptides such as 
substance p have an increased action in the SHR to enhance 
neurotransmission in sympathetic ganglia, this may 
contribute to hypertension by elevating blood pressure more 
in SHR than WKY rats. This idea was tested in the current 
study by comparing cardiovascular and renal sympathetic 
nerve responses of SHR versus WKY rats following intravenous 
injection of substance P. Responses to the ganglion 
nicotinic stimulant DMPP and the adrenoceptor stimulant 
norepinephrine were also evaluated in order to determine if 
changes in responsiveness were selective for SP.
CHAPTER 2 
Materials and Methods
This project was divided into six sets of experiments 
based on parameters measured, treatments, techniques, and 
the strain of rat that was used. Charles River Sprague- 
Dawley (CD) rats were used to develop the methodology for 
recording from the renal sympathetic nerve and to 
investigate the effects of various treatments such as 
pithing and baroreceptor denervation on responses to 
ganglion stimulation. SHR and WKY rats were used to 
determine if blood pressure, heart rate and renal nerve 
responses to sympathetic ganglion stimulation were enhanced 
in the SHR versus WKY. Though not shown in each instance, 
baseline blood pressures were significantly higher in all 
groups of SHR compared to WKY rats.
Source of Animals 
Male 8-10 week old SHR and WKY rats were obtained from 
Charles River Labs (Research Triangle Park, NC) and allowed 
to acclimatize for 1-3 weeks prior to each experiment. Male 
CD rats were taken from an active breeding colony maintained 
by the Department of Laboratory Animal Resources (breeders 
were from Charles River Laboratories) at the Quillen College 
of Medicine (Johnson City, TN).
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Source of Drugs 
Substance P was purchased from Bachem Inc., Torrance, 
CA. DMPP [1,l-dimethyl-4-phenylpiperazinium iodide] was 
from ICN Pharmaceuticals, Plainview, NY. Norepinephrine 
[(-)-arterenol bitartrate], (±)-propranolol, and gallamine 
triethiodide were from Sigma Chemical Co., St. Louis, HO. 
Chlorisondamine chloride [Ecolid] was from CIBA 
Pharmaceutical Co., Summit, NJ. Phenoxybenzamine HC1 was 
from Smith Kline & French Labs, Philadelphia, PA.
Statistical Methods 
Blood pressure, heart rate and renal sympathetic nerve 
responses to each dose of each drug as well as basal levels 
of blood pressure and nerve activity are compared between 
strains (SHR vs. WKY) and between groups (control vs. 
sinoaortic denervated or control vs. ganglion blocked) by a 
one-way analysis of variance (F-test). Significant 
differences are assigned at a probability level of less than
0.05 (p<0,05) and indicated in figures by an asterisk (*).
General Procedures 
Rats were anesthetized with an initial intraperitoneal 
injection of 55-65 mg/kg sodium pentobarbital (65 mg/ml). 
Supplemental intravenous injections of 10-20 mg/kg were 
given periodically during the experiment to maintain the 
level of anesthesia. The trachea was cannulated to
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facilitate respiration. With the aid of a stereozoom 
microscope, polyethylene (PE) tubing containing heparinized 
saline was then inserted approximately 5 mm into the left 
jugular vein (PE 20, l unit heparin/ml) and right femoral 
artery (PE 50, 100 units heparin/ml) for administration of 
drugs and measurement of arterial pressure, respectively.
An initial dose of 50 units heparin sodium in 0.5 ml of 
saline was given to flush the arterial catheter and prevent 
clotting during the experiment. Subsequent drug injections 
were given in volumes of approximately 50 ^1, depending on 
rat weight. Up to three concentration-response curves to 
different drugs were constructed in each rat, depending on 
the stability of blood pressure and RSNA. The order in 
which different drugs were given was selected randomly, with 
drug injections being given stepwise from the lowest to the 
highest concentration. Blood pressure, heart rate and RSNA 
were allowed to return to normal and stabilize after each 
drug injection. The venous catheter was flushed with 100 pi 
of saline prior to the first injection of each drug.
Isolation of the Renal Nerve 
In experiments where renal nerve activity was 
monitored, the rat was next placed on its right side and the 
left kidney exposed through a 3 cm retroperitoneal flank 
incision just below the diaphragm. The kidney was retracted 
ventrally and secured, with care taken to avoid disruption
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of renal blood flow. With the aid of a fiber-optic lamp and 
under magnification, the perirenal fat and connective tissue 
were carefully dissected to expose a renal nerve. This 
nerve is found lying near the junction of the abdominal 
aorta and renal artery in CD rats or about 1 cm 
rostroventral to this in SHR and WKY rats. The nerve was 
covered with heavy mineral oil to prevent drying and 
carefully freed from surrounding tissue for a length of 5-10 
mm Bipolar silver electrodes (diameter 0.008") were placed 
under the nerve, raised gradually, and secured in a position 
of stable contact. Responses were measured only from 
preparations in which nerve recordings exhibited 
baroreceptor sensitive pulse-synchronous activity.
Artificial Respiration 
Spontaneously breathing rats were used during the first 
three studies (i.e. the effect of SP on blood pressure and 
heart rate, stimulation of RSNA by SP, and effect of 
ganglion blockade on responses to SP in SHR and WKY rats). 
All rats in other studies were paralyzed and placed on 
artificial respiration at the start of the experiment. This 
was necessary in pithed and baroreceptor denervated rats 
because of an inability of the rat to ventilate itself. 
Control and adrenoceptor-blocked rats were also artificially 
ventilated for appropriate group to group comparison of 
responses. Neuromuscular blockade was effected by
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intravenous injection of 50 /unol/kg gallamine triethiodide, 
a concentration which produces neuromuscular blockade 
without affecting ganglionic neurotransmission (experimental 
observations). Immediately following cessation of 
respiration, rats were ventilated at a rate of 70-80/min. 
with a humidified 100% oxygen/room air mixture using a Model 
683 Harvard Rodent Ventilator. Tidal volume was adjusted 
for dead space, rat weight and respiratory rate in the range 
of 1.5-2.5 ml based on documented respiratory parameters 
provided with the ventilator,
Baroreceptor Denervation 
Bilateral sinoaortic denervation was performed by 
exposing the carotid sinus and both vagi for a length of 
approximately 2 cm The aortic depressor nerve was 
identified and cut, followed by removal of the superior 
cervical ganglion. Next, using a very fine forceps, the 
carotid sinus was stripped of all adventitia from 
approximately 1 cm above to l cm below the bifurcation of 
the internal carotid and external carotid arteries. This 
area was painted with a solution of 10% phenol in saline and 
allowed to sit for 5 minutes. Both vagi were then cut, and 
artificial respiration initiated. Sinoaortic denervation 
was deemed successful if no decrease in renal sympathetic 
nerve activity was observed following injection of 10-20 
nmol/kg norepinephrine.
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Pithlna
Rats were pithed by insertion of a 2 mm diameter steel 
rod through a small incision into the spinal column at the 
level of the first cervical vertebrae. The rod was advanced 
through the entire length of the spinal cord, then the 
direction reversed for destruction of the brain stem. 
Artificial respiration was initiated immediately following 
this maneuver*
Measurement of Blood Pressure and Heart Rate
A. Equipment
Systemic arterial pressure was measured by a Statham 
pressure transducer and amplified by a Gould Universal 
Amplifier, Model 13-4615-58. Heart rate was determined from 
the frequency of arterial pressure pulses by a Gould Biotach 
Amplifier, Model 13-G4615-66. Signals were relayed to a 
Gould Brush model 2400 pen writing recorder for analysis.
B. Data Analysis
Drug-induced changes in heart rate were calculated by 
subtracting pre-drug values from the maximum heart rate 
observed following drug injection. Mean arterial pressure 
was approximated as two-thirds of diastolic pressure plus 
one-third of systolic pressure. Values were measured at the 
point of maximum change in diastolic pressure.
25
Two different methods were used to measure blood 
pressure responses to substance P. In the first set of 
experiments, mean arterial pressure was measured at two 
points following injection of SP (figure 1). The first 
measurement was taken at the point of maximum decrease in 
pressure immediately following injection of sp (point #1). 
Mean arterial pressure at this point was subtracted from the 
pre-drug value thus giving a negative number. The second 
measurement was taken at the apex of the transient increase 
in pressure observed following high doses of SP (point #2). 
Point #1 is subtracted from point #2 thus giving zero or a 
positive number. This method, which takes into account both 
the vasodilatory and sympathoexcitatory effects of SP was 
used in analysis of blood pressure responses to SP in the 
first set of experiments. In the remainder of the 
experiments, mean arterial pressure was measured at point #2 
(occurring about 20 seconds after SP injection) and compared 
to the pre-drug value. Although this method does not 
distinguish between vasodilatory and sympathoexcitatory 
effects of SP, it was felt that it contained less 
variability and when combined with measurements of renal 
nerve activity would provide adequate information.
26
Points for Measurement of the 
Blood Pressure Response to SP
0,3 nmol/kg 
Substance P
32 nmol/kg 
Substance P
£ 100-
01
#1#1 #2 100-
< • i i • i * i i « i i i i • • I i i * i t i ■ i • * • i
-10 0 10 20 30 40 50 60 
Tina after drug (seconds)
0 10 20 30 40 50 60
Tine after drug (seconds)
Figure 1: Blood pressure responses to substance P. The first 
method used to assess responses measured two points. The 
vasodilatory response was evaluated by measuring mean arterial 
pressure at point #1 and comparing it to the pre-drug value. 
The sympathoexcitatory response was evaluated by measuring 
mean arterial pressure at point #2 and comparing it to point 
#1. A second method used to measure the blood pressure 
response measured only a single value by comparing point #2 to 
the pre-drug value.
Renal nerve recordings were performed inside a 2.5x4x2* 
cast iron cage (open at the front) for isolation from 
extraneous electrical noise. Bipolar nerve signals were 
amplified approximately 20,000 times in three stages using a 
Grass P15 AC Preamplifier (bandpass 3-1000 Hz, gain=10), a 
Gould Isolated Preamplifier, Model 13-5407-58 (gain»20), and 
a Gould Universal Amplifier, Model 13-4615-58 (bandpass 3- 
1000 Hz, gain=100). Nerve signals were also relayed 
directly from the Grass preamplifier to a Tektronix Type
Renal Sympathetic Nerve Recordings
A. Equipment
561B Oscilloscope for visualization. The Grass and Gould 
preamplifiers were placed inside the iron cage to provide 
high impedance (200 and 1000 megohm, respectively) 
differential amplification (with common mode rejection) of 
nerve signals close to the source. A grounding circuit was 
created by wire connections from the cage to five locations: 
the rat, the Grass preamplifier, the Gould preamplifier, the 
rodent ventilator, and earth. The rat was also connected to 
ground on the Grass preamplifier. Raw renal sympathetic 
nerve activity was transferred from the Gould Universal 
Amplifier to a Gould Integrator Amplifier, Model 13-4616-70 
(time constant « 1 second) and also (in the last set of 
experiments only) to a R.C. Electronics ISC-16 Analog to 
Digital converter card (sample rate = 2000 Hz) installed in 
a Zenith Data Systems Z-station 433Dh computer. Hardcopy 
output from the computer is via a Hewlett-Packard Deskjet 
500 printer (figure 2).
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Figure 2: Equipment configuration for bipolar differential 
recording of renal sympathetic nerve activity. Raw renal 
nerve activity is output to an oscilloscope for visualization, 
to an integrator for continuous hardcopy monitoring and to a 
computer for spectral analysis. Arrows indicate signal wires, 
lines indicate ground wires.
B. Data Analysis 
Two methods were used for measurement of renal 
sympathetic nerve activity: integration and power spectral 
analysis. Spectral analysis was available only in the last 
set of experiments (effect of baroreceptor denervation on 
responses in SHR and WKY rats)♦ Previous experiments used
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integration as a means for measuring neural activity. 
Spectral analysis was used when available instead of 
integration because of advantages in data retrieval by 
computer and because of the ability of spectral analysis to 
analyze the character of nerve activity in addition to 
integrating its amplitude.
1. Integration 
Integration of nerve activity is a common method used 
to measure neural activity in multifiber nerve recordings 
(Hopp et al., 1986), consisting simply of a periodic 
summation of the signal amplitude. Integration of bipolar 
differential recordings is necessarily preceded by full-wave 
rectification to avoid cancellation of the signal due to its 
equivalent positive and negative composition. Full-wave 
rectification is accomplished within the circuitry of the 
integrator. Integrated signals must be reset periodically 
to maintain values within an acceptable range. This is also 
provided for by the integrator, which allows for either 
internal or external reset timing. In the current study, 
integrated nerve activity was reset by an internal timer at 
a frequency of 1 Hz In essence, this sets the resolution of 
the integrator to allow for measurement of changes in nerve 
activity occurring over an interval of tl second.
Of the four sets of experiments in which nerve activity 
was monitored, the integration method was used in the first
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three to quantitate nerve discharges. In these studies, 
values for relative nerve activity minus background noise 
were calculated by measuring the height in mm of individual 
integration spikes, converting to arbitrary units and then 
squaring this value. Arbitrary scaling was set to 5 
units/cm in the first two studies and 20 units/cm in the 
third, with 5 cm constituting a full scale deflection. 
Resulting relative nerve activity values were proportional 
to (volts/second)2, a measure of multifiber nerve activity 
which exhibits linearity with respect to both frequency and 
amplitude changes (Dulli et al., 1984). Background noise 
was taken as the minimum value of relative activity observed 
following baroreceptor activation or pithing.
2. Spectral Analysis 
Power spectral analysis of nerve recordings is a method 
which has recently received much attention, due in part to 
the increased availability of high-speed computers necessary 
for the analog to digital conversion and processing 
involved. The technique has advantages over other methods 
(such as integration) in that in addition to measuring 
signal amplitude, spectral analysis provides information 
about the nature of a signal's temporal structure. This 
data is useful since information contained in nerve 
discharges may be encoded in both frequency and amplitude 
components.
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Spectral analysis mathematically reduces bioelectric 
phenomena into frequency components of defined amplitude 
(figure 3). Thus, the signal may be expressed graphically 
with frequency usually represented on the x axis versus 
voltage on the y axis. This representation of a neurogram 
is termed the autospectrum. Power spectral analysis differs 
from simple spectral analysis in that amplitude is expressed 
in units of volts2, as opposed to volts. Theoretically, if 
the autospectrum of a nerve signal is known, that signal can 
be reconstructed exactly by reversing the mathematical 
transform. This mathematical transform is called the 
Fourier Transform. Several variants of the Fourier 
Transform exist, each with different applications under 
varying conditions. Continuous Fourier Transforms assume 
that the signal contains an infinite number of frequency 
components and are therefore expressed as a line or curve in 
the x-y domain. Discrete Fourier Transforms assume a finite 
number of frequency components, each separated by l/t Hz, 
where t = the duration of the source signal in seconds, and 
are expressed in a form similar to a histogram. A type of 
Discrete Fourier Transform which lends itself especially 
well to analysis of digitized signals is the Fast Fourier 
Transform (FFT) because it analyzes segments of data rather 
than attempting to transform a continuous wave form (Glaser 
and Ruchkin, 1976). The FFT was used for analysis of renal 
sympathetic nerve recordings in the current study.
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Renal sympathetic nerve activity was stored in digital 
format on a 200 megabyte fixed computer disk at a sampling 
rate of 2000 Hz. This data was analyzed by a FFT using the 
R.C. Electronics Computerscope Enhanced Graphics Acquisition 
and Analysis (EGAA) System software package. Neurograms 
were analyzed in 2 second segments, resulting in power 
spectra with a resolution of 1/2 Hz. Autospectrum exhibited 
both low (3-8 Hz) and high (10-500 Hz) frequency components, 
with most of the power being distributed between 100 and 200 
Hz (figure 3). The low frequency component corresponded to 
the rate of synchronized nerve discharge. This discharge 
was observed to occur most often during the diastolic phase 
of the cardiac cycle (figure 4). Power was transferred to 
the lower frequency component following rectification of the 
signal (figure 5), therefore this technique is useful for 
coherence analysis of synchronous nerve discharge. However, 
changes in the level of nerve activity were reflected as 
increases or decreases in the total power contained in 
autospectra of raw, unrectified neurograms, a measurement 
which was more useful in the current study than coherence 
analysis. Therefore, effects of ganglion stimulation or 
baroreceptor activation on renal nerve activity were 
measured by calculating changes in total power (contained in 
all frequencies) of the unrectified signal.
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Autospectrum of Efferent 
Renal Nerve Activity
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Figure 3: Autospectral analysis of a bipolar renal sympathetic 
nerve recording. Low frequency (approximately 5 Hz) and high 
frequency (100-200 Hz) components are displayed. The low 
frequency component corresponds to the rate of synchronous 
discharge. Total power contained in all frequencies of the 
autospectrum corresponds to relative nerve activity.
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Coherence of Arterial Pressure (AP) Pulse with 
Efferent Renal Sympathetic Nerve Activity (RSNA)
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0.0 0.5 1.0 1.5 2.0
Time in seco n d s
Figure 4: The temporal relationship of blood pressure and 
efferent renal sympathetic nerve activity is shown. Bursts 
occur most often in synchrony with the diastolic phase of the 
cardiac cycle.
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Figure 5: Autospectra1 analysis of a rectified bipolar renal 
sympathetic nerve recording. Power is primarily distributed 
to frequencies corresponding to the rate of synchronous 
discharge (about 5 Hz).
CHAPTER 3 
Results
The Effect of Substance P 
on Blood Pressure and Heart Rate 
Blood pressure and heart rate responses to intravenous 
injection of sp (0.03-30 nmol/kg), DMPP (0.03-3.0 jimol/kg) 
and NE (0.3-30 nmol/kg) were measured in 9-11 week old male 
SHR (n=4) and WKY (n=5) rats. Substance P increased heart 
rate and caused biphasic changes in blood pressure 
consisting of an initial decrease in pressure followed by a 
dose-dependent rise in blood pressure (figures 6,7).
R esponses of a Typical WKY Rat to Injection of 
Low (0.3 nmol/kg) and High Dose (32  nmol/kg) Substance P
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Figure 6: Typical changes in heart rate and blood pressure 
observed after injection of 0.3 and 32 nmol/kg substance P in 
a WKY rat.
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Responses of a Typical SHR to  Injection of 
Low (0.3 nmol/kg) and High Dose (32 nmol/kg) Substance P
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Figure 7: Typical changes in heart rate and blood pressure in an 
SHR following injection of 0.3 and 32 nmol/kg substance P.
Maximal decreases in blood pressure occurred approximately 
10 seconds after injection of SP. At high doses, this was 
followed by an increase in pressure reaching its maximum after 
about 20 seconds. Doses of SP greater than 3.0 nmol/kg 
increased pressure in SHR sufficiently to overcome the initial 
decrease. In contrast, this did not occur in WKY rats owing to 
the fact that the secondary increase in blood pressure due to SP 
was less than that observed in SHR (figure 8), while the initial 
decrease in pressure was greater (figure 9). Note; method #1 
described on pages 25-26 was used to measure blood pressure 
responses here.
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Increase (n Blood Pressure due to Substance P
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o WKY (n=5)
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Figure 8: Magnitude of the secondary increase in mean arterial 
pressure due to injection of substance P in SHR and WKY rats. 
Increases in pressure to 0.1-30 nmol/kg SP were significantly 
greater in SHR versus WKY rats, with the highest dose increasing 
pressure by 48.3 ± 6.9 vs. 12.0 ± 3.3 mmHg, respectively.
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Figure 9: Maximum decrease in mean arterial pressure due to 
substance P in SHR and WKY rats. Decreases in arterial pressure 
following 0.1-3.0 nmol/kg SP were significantly greater in WKY 
rats compared to SHR by an average of 13.7 mmHg.
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Tachycardia occurred following SP injection, with 
increases in heart rate being significantly greater in SHR 
compared to WKY rats (figure 10). The onset of this increase 
in heart rate was slightly delayed compared to blood pressure 
responses, reaching a maximum approximately 30-50 seconds 
after drug injection.
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Figure 10: Maximal increase in heart rate following injection 
of substance P in SHR and WKY rats. Increases in heart rate 
to 3.0-30 nmol/kg SP were statistically greater in SHR 
compared to WKY rats, with the highest dose increasing rate by 
90 ± 8 versus 21 ± 11 beats/min., respectively.
In contrast to the differences observed in responses to 
SP, pressor and tachycardic effects of DMPP and NE were 
similar in the two groups (figures 11-14). Tachycardic 
responses to NE were variable due to reflex bradycardia 
which occurred in some rats.
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Figures 11 £ 12: Increase in mean arterial pressure and heart 
rate due to the ganglion nicotinic agonist 1,1-dimethy1-4- 
phenylpiperazinium (DMPP) in SHR and WHY rats. Responses were 
similar between the two groups, with a statistical difference 
being observed only in the tachycardic effect of 0.3 /raol/kg 
DHPP.
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Figures 13 s 14: Increase in mean arterial pressure and heart 
rate due to the adrenoceptor stimulant norepinephrine in SHR 
and WKY rats. Ho statistical differences were seen between 
responses in the two groups.
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Stimulation of RSNA bv Substance P 
The technique for recording renal sympathetic nerve 
activity (RSNA) was developed in CD rats in order to provide 
a direct measurement of the effect of SP on postganglionic 
sympathetic nerve activity. Following intravenous injection 
of substance P (0.3-30 nmol/kg), a dose-dependent increase 
in RSNA was observed (figure 15a). This effect coincided 
with increases in blood pressure and heart rate, supporting 
the idea that pressor and tachycardic effects of SP result 
from increases in sympathetic tone. In addition, since 
these effects were not eliminated by ganglion blockade with 
20 pmol/kg chlorisondamine (figure 15b) or following 
destruction of the spinal cord by pithing (figure 15c), they 
are not due to an action on the central nervous system. 
Injection of 0.05 ml of vehicle did not affect RSNA, blood 
pressure or heart rate (figure 16). These observations 
support the idea that SP stimulates sympathetic ganglia 
following high dose (£ 3.0 nmol/kg) intravenous injection.
GANGLION
BLOCXAOE
PITHING
Figure 15: Effect of 30 nmol/kg substance P on heart rate, 
blood pressure, and renal sympathetic nerve activity (RSNA) in 
CD rats. Both raw and integrated RSNA are shown. Control
responses are shown in panel A. Panel B shows a typical
response following ganglion blockade (with 20 pmol/kg
chlorisondamine). Panel C shows the response after
destruction of the central nervous system by pithing. Drug 
injections are indicated by an arrow above the blood pressure 
tracing. Each panel depicts 75 seconds of data.
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Figure 16: The effect of injection of 50 fil vehicle (normal 
saline) on blood pressure and RSNA in a CD rat* Injection is 
indicated by an arrow above the blood pressure tracing, A 
small transient increase in blood pressure is observed which 
has no significant effect on RSNA. 75 seconds of data are 
shown.
Effect of Ganglion Blockade on 
Responses to SP in SHR and WKY rats 
Blood pressure, heart rate and RSNA responses to 
intravenous injection of SP (0.3-30 nmol/kg) were measured 
in 10-12 week old male SHR (n=9) and WKY (n=6) rats before 
and following blockade of ganglion nicotinic receptors with 
chlorisondamine (20 /xmol/kg). Cardiovascular responses to 
SP prior to ganglion blockade were similar to those observed 
previously in SHR and WKY rats. Biphasic blood pressure 
responses were evaluated by measuring mean arterial pressure 
approximately 20 seconds following injection of SP at the 
point of maximal increase in pressure (refer to figure 1).
Differences in the blood pressure response to 1.0-30 
nmol/kg SP were seen in SHR compared to WKY rats prior to 
ganglion blockade, with 3.0-30 nmol/kg SP increasing 
pressure above baseline only in SHR (figure 17). These 
differences were reduced after ganglion blockade, with 
increases in pressure to 3.0-30 nmol/kg SP being exhibited 
in both SHR and WKY rats (figure 18). Note: this was likely 
due to the fact that mean arterial pressure was reduced 
following ganglion blockade, resulting in attenuation of 
vasodilatory effects of SP.
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Change in MAP 20 sec Following Substance P 
Injection in SHR and WKY rats
40
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o WKY (n=6)
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Figure 17: The change in mean arterial pressure (HAP) 20 
seconds after injection of substance P in SHR and WKY rats.
Change in MAP 20 sec Following i.v. Substance P 
in SHR and WKY rats after Ganglion Blockade
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Figure 18: The change in mean arterial pressure (MAP) 20 
seconds after injection of substance P in SHR and WKY rats 
after ganglion blockade with 20 junol/kg chlorisondamine.
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The magnitude of intrinsic RSNA in SHR was nearly twice 
that in WKY rats (154 ± 18 versus 80 ± 8.5, arbitrary units). 
In addition, this ratio was maintained after ganglion 
blockade with 20 jtmol/kg chlorisondamine (46 ± 8.5 versus 22 
± 5.8 units, figure 19). Relative nerve activity is measured 
in arbitrary units proportional to (volts/second)2.
Renal Sympathetic Nerve Activity in SHR and WKY rats 
Before and After Ganglion Blockade
I | Control 
154 t is ■  Ganglion Blockade
[chlorliondtmlne] * 20 umol/kg 
• » p < 0.05 vs. SHR
a loo 80  t  8 .5
46 i 8.5
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22 i  5.8
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(n=5 ,4)
WKY
(n=5,5)
Figure 19: Relative renal sympathetic nerve activity (RSNA) in 
SHR and WKY rats before and following ganglion blockade with 
20 pmol/kg chlorisondamine. RSNA is significantly greater in 
SHR compared to WKY rats both before and after ganglion 
blockade.
SP enhanced RSNA in both SHR and WKY rats. This 
increase was preceded by a slight decrease in nerve activity 
which was particularly apparent in SHR (figure 20). This 
inhibition of RSNA predominated over stimulatory effects of 
SP at lower doses and attenuated the increase in RSNA 
observed at high doses. Perhaps due to this effect, no 
significant differences were observed in RSNA responses to 
SP in control SHR and WKY rats (figure 21).
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Figure 20: Typical changes in blood pressure, raw renal 
sympathetic nerve activity (RSNA) and integrated RSNA in SHR 
and WKY rats due to 30 nmol/kg substance P (SP).
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Figure 21: Change in renal sympathetic nerve activity 20 
seconds after substance P injections in SHR and WKY rats. 
Nerve activity is expressed in arbitrary units proportional to 
(volts/sec) . No significant differences in the response are
exhibited.
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It is interesting to note that a similar inhibition of 
RSNA is observed following injection of NE, which is likely 
to be due to activation of baroreceptors (figure 22). Since 
only stimulatory effects of SP on RSNA are seen following 
ganglion blockade (figure 23), renal nerve responses to SP 
were evaluated following blockade of ganglion nicotinic 
receptors with chlorisondamine (20 /mol/kg).
After ganglion blockade, SHR exhibited an enhanced RSNA 
response to SP, but this was statistically significant at 
only one dose (3 nmol/kg). Differences in stimulation of 
RSNA following injection of 10-30 nmol/kg SP in SHR and WKY 
rats did not achieve statistical significance due to large 
variability in the response (figure 24). Excessive lowering 
of basal blood pressure by chlorisondamine in some rats may 
have caused a lack of responsiveness which contributed to 
this variability.
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NE
IQ nm o l/k g
1 minute
Figure 22: A typical blood pressure, raw renal sympathetic 
nerve activity (RSNA) and integrated RSNA response to 10 
nmol/kg norepinephrine (NE).
„ SP 
30 nmol/kg 3 0  r v n o l / k g
1 minute Ganglion
Blockade
1 minute
Figure 23: Typical blood pressure, raw renal sympathetic nerve 
activity (RSNA) and integrated RSNA responses to 30 nmol/kg 
substance P (SP) prior to (left panel) and following (right 
panel) ganglion blockade with 20 pmol/kg chlorisondamine.
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Change in Renal Sympathetic Nerve Activity due to 
Substance P after Ganglion Blockade in SHR and WKY rats
[chloriiondaaina] ■ 20 unol/kg350
■ SHR (n=4)
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Figure 24: Change in renal sympathetic nerve activity due to 
substance P in SHR and WKY rats following ganglion blockade 
with 20 /raol/kg chlorisondamine.
Baroreceptor Mediated Control of RSNA 
Purina Ganglion Stimulation with PMPP 
Blood pressure, heart rate and RSNA responses to DHPP 
(0.03-1.0 ^mol/kg) were obtained in male CD rats (300-475g). 
Dose-response curves for the increase in RSNA were 
constructed in control (n=6), sinoaortic denervated (SAD, 
n=5), pithed (n=5), and adrenoceptor blocked (n«5) groups. 
All groups were paralyzed by injection of 50 jiraol/kg 
gallamine triethiodide and artificially respired.
Ganglion stimulation by DMPP was found to have complex 
effects on RSNA in control rats consisting of both
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stimulatory and inhibitory influences. The elevation in 
blood pressure caused by DMPP lead to baroreceptor 
activation which reflexively decreased RSNA. in contrast, 
the direct effect of DHPP on ganglion nicotinic receptors is 
to increase sympathetic tone. At low doses of DMPP (£ 0.1 
Mmol/kg) baroreceptor-induced inhibition of RSNA 
predominated. In many instances no increase in RSNA was 
observed even though DHPP increased blood pressure (data not 
shown). Higher doses were characterized by a brief (2-5 
second) but substantial increase in RSNA followed by long- 
lasting inhibition of nerve activity (figure 25).
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Figure 25: Typical change in heart rate, blood pressure, raw 
renal sympathetic nerve activity (RSNA) and integrated RSNA 
following injection of 0.56 ^mol/kg 1,1-dimethyl-4- 
phenylpiperazinium (DHPP) in a control (untreated) CD rat.
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The effect of DMPP to inhibit RSNA was eliminated 
following SAD or destruction of the central nervous system 
by pithing (figures 26,27), indicating that it is due to 
activation of baroreceptors. This idea is supported by 
experiments employing the a-adrenoceptor antagonist 
phenoxybenzamine (30 nmol/kg), in which the inhibitory 
effect of baroreceptor activation was prevented by blocking 
the effect of DMPP to increase arterial pressure. Following 
a-adrenoceptor blockade, DMPP exhibited a depressor effect 
and the stimulatory action of DMPP on RSNA was enhanced and 
prolonged (figure 28). Propranolol (5 /mol/kg) was given to 
a-adrenoceptor blocked rats to eliminate fi-adrenoceptor 
mediated depressor effects of DMPP, which may also affect 
RSNA. Under these circumstances the initial DMPP induced 
increase in RSNA was also enhanced but was followed by a 
small increase in blood pressure and slight inhibition of 
RSNA (figure 29).
No statistical differences were observed in the maximum 
stimulation of RSNA by DMPP in SAD vs. adrenoceptor blocked 
groups (data not shown). Responses to 0.56 jxmol/kg DMPP 
were significantly increased in SAD vs. control rats over 
the entire time course of the response. In addition, 
baseline RSNA was significantly elevated by baroreceptor 
denervation. Responses of pithed animals to DMPP were 
attenuated compared to control (figure 30).
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Figures 26 6 27: Typical changes in heart rate, blood
pressure, raw renal sympathetic nerve activity (RSNA) and 
integrated RSNA following injection of 0.56 praol/kg 1 ,1 - 
dimethyl-4-phenylpiperazinium (DMPP) in baroreceptor 
denervated (left panel) or pithed (right panel) CD rats. 
Inhibitory effects of DMPP on RSNA are eliminated following 
these procedures, although a transient decrease in RSNA is 
sometimes observed in SAD rats immediately following the 
stimulatory effect of DMPP.
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Figures 20 0 29: Typical changes in heart rate, blood
pressure, raw renal sympathetic nerve activity (RSNA) and 
integrated RSNA following injection of 0.56 /mol/kg 1,1- 
dimethyl-4-phenylpiperazinium (DMPP) in a CD rat after a- 
adrenoceptor blockade with 30 /imol/kg phenoxybenzamine (left 
panel) or combine a- and B-adrenoceptor blockade with 
phenoxybenzamine (30 jmol/kg) and propranolol (5 /imol/kg).
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Time Course of Efferent Renal Nerve 
Activity Following DMPP Injection
10000
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Figure 30: Tine course of efferent renal nerve activity before 
and after injection of 0.56 /irool/kg 1, l-dimethyl-4- 
phenylpiperazinium (DMPP) in control, pithed, and sinoaortic 
denervated CD rats.
Blood pressure responses to SP (0.3-32 nmol/kg) were 
measured in paralyzed, ventilated 10-12 week old male SHR 
(n=5) and WKY (n=5) rats before and following adrenoceptor 
blockade with phenoxybenzamine (10 /imol/kg) and propranolol 
(5 jimol/kg). Adrenoceptor blockade was employed to prevent 
the effect of SP to increase blood pressure, thus allowing 
for comparison of depressor responses to SP in SHR and WKY 
rats. Because SP is a less powerful pressor agent than
Effect of Adrenoceptor Blockade on 
Blood Pressure Responses to Substance P
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DMPP, a lower concentration of phenoxybenzamine was 
necessary here than was previously employed to block the 
pressor effects of DMPP (10 versus 30 /unol/kg, 
respectively).
Cardiovascular responses to SP prior to adrenoceptor 
blockade were similar to those observed in previous studies 
(figure 31), although some differences were observed (see 
chapter 4, p.71). Adrenoceptor blockade lowered mean 
arterial pressure more in SHR than WKY rats (figure 32). 
Pressor effects of SP were eliminated by a-adrenoceptor 
blockade (figure 33). Depressor effects of SP were also 
attenuated, perhaps due to the lower baseline blood 
pressures exhibited after adrenoceptor blockade. Depressor 
effects of SP were attenuated in SHR compared to WKY rats, 
with the greatest difference being exhibited at the two 
highest doses of SP. This difference in response to high 
doses of SP was not prevented by increasing the 
concentration of phenoxybenzamine (data not shown).
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Change In MAP 20 sec Following Substance P 
in SHR and WKY rats
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Figure 31: The change in mean arterial pressure (MAP) 20 
seconds after injection of substance P in SHR and WKY rats. 
Blood pressure responses of SHR were significantly different 
from WKY rats at all doses tested (p < 0.05, one-way ANOVA).
Arterial Pressure of SHR and WKY rats Before 
and After Adrenergic Blockade
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Figure 32: Baseline mean arterial pressures in SHR and WKY 
rats prior to and following adrenoceptor blockade with 10 
pmol/kg phenoxybenzamine and 5 /jmol/kg propranolol.
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rats After Adrenergic Blockade
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Figure 33: The change in mean arterial pressure (HAP) 20 
seconds following injection of substance P in SHR and WKY rats 
after adrenoceptor blockade with 10 /mol/kg phenoxybenzamine 
and 5 pmol/kg propranolol.
Effect of Baroreceptor Denervation on 
Cardiovascular and RSNA Responses to SP. DMPP and NE 
Blood pressure, heart rate and RSNA responses were 
measured following intravenous injection of SP (0.3-32 
nmol/kg), DMPP (0.1-1.0 /mol/kg), and NE (0.3-32 nmol/kg) in 
paralyzed, ventilated 10-13 week old male SHR and WKY rats. 
Both baroreceptor-intact (SHR, WKY) and sinoaortic 
denervated rats (SHR-d, WKY-d) were used. SHR exhibited 
greater intrinsic RSNA and less enhancement of RSNA 
following SAD than WKY rats (figure 34). In addition, 
differences were observed in the character of nerve 
recordings (figure 35).
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Figure 34: Total power o£ baseline renal sympathetic nerve 
activity before and after sinoaortic denervation in SHR and 
WKY rats.
Ran Basal E fferen t Renal Nerve Activity in 
Control and Sinoaortic Denervated SHR and WKY ra ts
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Figure 35: Typical renal nerve recordings from baroreceptor- 
intact (SHR, WKY) and sinoaortic denervated (SHR-d, WKY-d) 
rats.
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Prior to baroreceptor denervation, pulsatile nerve 
activity in SHR was greater both in magnitude and frequency 
compared to WKY rats. However, this difference was abolished 
following s a d .
Denervation significantly enhanced responses to ganglion 
stimulation by SP (figure 36) and DMPP (figure 37), although 
no significant differences were seen between SHR and WKY or 
SHR-d and WKY-d. However, because RSNA varied greatly during 
experiments, responses were more accurately represented when 
expressed as a percent of the baseline RSNA immediately prior 
to drug injection. When measured in this manner, SHR-d did 
exhibit an elevated RSNA response to high doses of SP when 
compared to WKY-d (figure 38). Similar differences were not 
observed in the response to DMPP (figure 39).
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Figure 36: Maximum total power measured per second in renal 
sympathetic nerve discharges before and following intravenous 
injection of substance P in control SHR and WKY rats and 
following baroreceptor denervation (SHR-d, WKY-d). Substance 
P concentration is in mol/kg. Denervation of baroreceptors 
enhanced RSNA responses to 1.0-32 nmol/kg SP.
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Figure 37: Maximum total power measured per second in renal 
sympathetic nerve discharges before and following intravenous 
injection of l,l-dimethyl-4-phenylpiperazinium (DMPP) in 
control SHR and WKY rats and following baroreceptor 
denervation (SHR-d, WKY-d), DMPP concentration is in mol/kg. 
Denervation of baroreceptors enhanced RSNA responses to all 
doses of DMPP.
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Percent Increase In Total Power of Renal Nerve 
Activity Following Substance P Injection
600
■ SHR-d (n=5) 
•  WKY-d (ns5)
500
<
%a  400 
c
5j 300
(d
| 200 
100
-9.5 -8.5 - 8.0 -7.5
Log [Substance P] (mol/kg)
Figure 38: Percent increase in maximum total power of renal 
sympathetic nerve discharges following substance P injection 
in SHR and WHY rats.
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Figure 39: Percent increase in maximum total power of renal 
sympathetic nerve discharges following injection of 1,1- 
dimethyl-4-phenylpiperazinium in SHR and WKY rats.
Blood pressure responses to SP in control and 
denervated SHR and WKY rats were comparable to those 
obtained in previous studies (figure 31). Compared to WKY 
rats, SHR exhibited a slightly greater increase in pressure 
due to DMPP (figure 40), but not to NE (figure 41). Heart 
rate responses were complex. Although reflex bradycardia 
was not seen following SAD, basal heart rate was frequently 
increased and drug-induced increases in heart rate were 
blunted. Responses to SP were enhanced in control SHR 
(figure 42). No other differences were seen in heart rate 
responses with the exception of a slight increase in the 
response of SHR-d to DMPP (figure 43).
Increase In Mean Arterial Pressure Following 
DMPP Injection in SHR and WKY rats
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Figure 40: Increase in mean arterial pressure observed
following injection of l,l-dimethyl-4-phenylpiperazinium 
(DMPP) in SHR and WKY rats.
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Increase in Arterial Pressure Following 
Norepinephrine Injection in SHR and WKY rats
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Figure 41: Increase in mean arterial pressure observed
following injection of norepinephrine in SHR and WKY rats.
Increase in Heart Rate Following Substance P 
Injection in SHR and WKY rats
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Figure 42: Increase in heart rate observed following injection 
of substance P in SHR and WKY rats.
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Increase in Heart Rate Following DMPP Injection 
in Sinoaortic Denvervated SHR and WKY rats
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Figure 43: Increase in heart rate observed following injection 
of 1,l-dimethyl-4-phenylpiperaziniwn (DMPP) in baroreceptor 
denervated SHR and WKY rats.
CHAPTER 4 
Discussion
The enhanced renal sympathetic responsiveness of SHR 
versus WKY rats to SP observed in the current study 
indicates that SP may be involved in the elevation in basal 
and environmentally evoked sympathetic discharges observed 
in this model of hypertension. In addition, an attenuation 
of the depressor effect of SP in SHR was observed which is 
in agreement with previous studies (Virus et al., 1981).
The origin of these changes in cardiovascular and 
sympathetic responsiveness to SP in SHR is not known. 
However, it is possible that they are causally linked.
Studies have shown that sympathetic ganglia are 
surrounded by a dense network of substance F-immunoreactive 
fibers (Hokfelt et al., 1977). These appear to be sensory 
in origin, arising as collateral branches of primary sensory 
neurons with terminations in the periphery (Baker et al., 
1980; Dalsgaard et al., 1982; Matthews and Cuello, 1982).
It has been proposed that in addition to sending information 
to the dorsal spinal cord, stimulation of peripheral 
terminals of primary sensory neurons may cause the release 
of SP in sympathetic ganglia where it facilitates nicotinic 
neurotransmission (Konishi and Otsuka, 1985). This raises 
the possibility that reflex modulation of sympathetic tone
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nay occur outside of the central nervous system. Since the 
heart and vasculature are densely innervated by both sensory 
and sympathetic nerves, this reflex nay be important for 
regulation of cardiovascular function (figure 44). This 
proposal is supported by two lines of evidence.
First, the release of substance P in sympathetic 
ganglia appears to play an important role in modulation of 
sympathetic tone. Several studies have shown that SP has a 
stimulatory effect in sympathetic ganglia (Otsuka and 
Yoshioka, 1993). For example, iontophoretic application of 
SP to sympathetic postganglionic neurons produces a delayed 
onset long lasting depolarization which is blocked by SP 
antagonists (Konishi and otsuka, 1985). This stimulatory 
action of SP lowers the threshold for excitation of ganglion 
neurons and can even initiate a burst of action potentials 
(Tsunoo et al., 1982).
Secondly, modulation of sympathetic tone by SP probably 
plays an important role in cardiovascular regulation. 
Depletion of SP in the whole animal by neonatal treatment 
with capsaicin reduces blood pressure and impairs reflex 
compensation to hemorrhage or vasodilators (Donnerer and 
Lembeck, 1989). In contrast, intravenous injection of SP in 
low nanomolar concentrations increases heart rate and blood 
pressure (Hancock, 1992). Thus, SP released from sensory 
nerve terminals in sympathetic ganglia is likely to exert a 
significant influence on the cardiovascular system and may 
be necessary for the maintenance of normal sympathetic drive.
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Figure 44: The circuitry involved in substance P-mediated
modulation of neurotransmission in sympathetic ganglia. Sensory 
neurons of the dorsal root ganglion with perivascular nerve 
terminals give off collateral branches which innervate 
sympathetic ganglia. Sensory stimuli in the vasculature may 
potentially lead to the release of substance P (SP) in 
sympathetic ganglia, where it facilitates neurotransmission. 
Presynaptic modulation of SP and acetylcholine (ACh) release by 
enkephalins (Enk) may also be involved (from Rand et al., 1990).
If modulation of sympathetic tone by SP in sympathetic 
ganglia is important in peripheral regulation of the 
cardiovascular system, then it is also possible that SP may be 
involved in cardiovascular disorders. Spontaneously 
hypertensive rats were used in the current study to test the 
proposal that changes in the peripheral action of SP to 
increase sympathetic tone may contribute to the development of 
hypertension. Information from several studies supports this 
idea, particularly in regard to the SHR model of hypertension.
For example, there is abundant evidence that sympathetic 
overactivity contributes to development of hypertension in the 
SHR (Ekas and Lokhandwala, 1981; Folkow, 1989; Magee and
Schofield, 1992; Palermo et al., 1981). In addition, this 
elevation in sympathetic tone is apt to be due in part to 
changes in the sensitivity of sympathetic ganglia. It has 
been demonstrated that in SHR, superior cervical ganglion 
neurons exhibit increased excitability to intracellular 
stimulation (Yarowski et al., 1981). Evidence that SP is 
involved in this enhanced sensitivity is provided by recent 
observations that superior cervical ganglia of SHR exhibit 
elevated SP-immunoreactivity compared to ganglia of WKY 
rats. Gurusinghe and Bell (1989) have demonstrated that 
compared to WKY rats, approximately 2-3 times as many 
principal cells of superior cervical ganglia in SHR are 
invested by SP-immunoreactive varicosities. This was not 
due simply to a greater number of ganglion cells since no 
differences were observed in the total number of neurons. 
Thus, these observations indicate that excessive sympathetic 
drive in SHR may be generated in part at the ganglionic 
level by greater actions of SP to increase excitability of 
ganglion neurons and enhance nicotinic neurotransmission.
In the present study, dose-dependent increases in blood 
pressure, heart rate, and renal sympathetic nerve activity 
were observed following intravenous injection of SP in both 
SHR and WKY rats. These effects persisted following 
ganglion blockade, pithing, and sinoaortic denervation, 
suggesting that they are due to a direct action of SP to 
stimulate postganglionic sympathetic nerve activity. This 
is in agreement with previous observations by Hancock (1992)
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on the effects of SP on blood pressure and heart rate In CD 
rats.
Increases in blood pressure due to SP were consistently 
much greater in SHR than in WKY rats, supporting the idea 
that ganglion actions of SP are enhanced in SHR. Some 
differences were observed between different groups of SHR 
and WKY rats (compare figures 17 and 31). However, these 
dissimilarities are probably due to the fact that artificial 
respiration was employed in some sets of experiments (figure 
31) but not in others (figure 17). Artificially ventilated 
rats are not subject to decreases in respiratory rate which 
can occur following injection of SP. This inhibition of 
respiration probably also has effects on blood pressure. 
However, it cannot account for differences in blood pressure 
responses seen between SHR and WKY rats.
Differences in the blood pressure response to SP in SHR 
and WKY rats did not appear to be caused by generalized 
changes in sensitivity to ganglion stimulation since pressor 
responses to DMPP in the two groups were similar. In 
addition, the pressor effects of NE were nearly identical in 
SHR and WKY rats, suggesting that differences in the effects 
of SP on arterial pressure were not due to enhanced a- 
adrenoceptor responsiveness of SHR. However, since SP also 
transiently decreased blood pressure, it is possible that 
this influenced measurement of increases in blood pressure. 
This idea is discussed in more detail below.
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It should be noted here that an Increased vascular 
responsiveness to catecholamines has been reported in SHR 
(Sun and Hanig, 1983; Folkow, 1986}, which is exaggerated by 
cardiovascular hypertrophy occurring in older SHR. The use 
of young adult SHR and WKY rats (9-13 weeks of age) in the 
current study may explain this lack of increase in 
vasoconstriction to norepinephrine.
As in the case of the blood pressure response, 
tachycardic effects of SP were greatly exaggerated in SHR 
compared to WKY rats, consistent with an increased action of 
SP in SHR to enhance sympathetic drive to the heart.
However, a slight enhancement in the tachycardic response to 
DMPP was also observed. Because DMPP increases blood 
pressure markedly and thereby activates arterial 
baroreceptors, differences in heart rate responses to DMPP 
could conceivably be explained by attenuation of baroreflex 
control of heart rate in the SHR. This idea is supported by 
previous studies (Harada et al., 1992}. This is not the 
case, however, since differences were exhibited both in 
control and in baroreceptor denervated rats. Since both SP 
and nicotinic stimulants can stimulate epinephrine release 
from adrenal chromaffin cells (Zhou and Livett, 1990}, and 
previous studies have shown that much of the tachycardic 
effect of SP results from adrenomedullary stimulation 
(Hancock, 1992), it is possible that sensitivity of the 
adrenals is non-specifically enhanced in SHR and this may 
account for the increased tachycardic response to DMPP.
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This idea could be tested by comparing heart rate responses 
to DMPP in SHR and WKY rats before and after bilateral 
adrenalectomy. The sensitivity of flj^-adrenoceptors did not 
appear to be altered in SHR since tachycardic effects of NE 
in SHR and WKY rats were not different.
Substance P also decreased blood pressure more in WKY 
rats than SHR, an action which precedes its effect to 
increase blood pressure. This depressor action of SP is 
believed to be mediated by NKx receptors located on 
endothelial cells (Otsuka and Yoshioka, 1993; Regoli et al., 
1990) which release endothelium-derived relaxing factor 
(EDRF). Endogenous activation of these receptors is thought 
to occur via an axon reflex mechanism resulting in the 
release of SP from sensory terminals in the vasculature.
The effect of SP to decrease arterial pressure more in WKY 
rats than SHR is not surprising since blunting of 
endothelium-dependent vasodilatory responses in SHR has been 
noted in several studies (Luscher et al., 1992). In 
addition, attenuation of depressor responses to SP in SHR 
has previously been observed (Virus et al., 1981; Pompei et 
al., 1993) and attributed to a decrease in endothelial cell 
mediated vasodilation.
Attenuation of SP-induced vasodilation probably 
contributes to the elevation in arterial pressure above 
baseline observed in SHR following high doses of SP. This 
is likely since vasodilatory effects of SP directly 
antagonize the constrictor influences of neurally released
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norepinephrine on vascular smooth muscle cells. If 
antagonism of vasoconstriction by SP is less in SHR, this 
would lead to greater increases in arterial pressure 
following stimulation of sympathetic ganglia.
Ganglion blockade with 20 pmol/kg chlorisondamine 
greatly decreased baseline RSNA in both SHR and WKY rats, 
though comparatively less so in WKY rats than SHR. It 
should be noted here that nerve activity following ganglion 
blockade contained spiking activity which was significantly 
above the level of background noise, as evaluated 12 hours 
after death. This is in conflict with the common practice 
in some studies of setting background noise levels to those 
observed after ganglion blockade. The meaning of this 
residual activity is somewhat ambiguous since the origin of 
potentials remaining after ganglion blockade is unclear. An 
obvious but unproven hypothesis is that they are generated 
by the stimulant action of a noncholinergic transmitter, 
perhaps substance P.
Following injection of SP in SHR and WKY rats, renal 
nerve discharges exhibit a gradual increase in frequency and 
amplitude. This coincides with the increase in blood 
pressure, supporting the proposition that they are causally 
linked. Both responses reached a maximum after about 20 
seconds, then decayed slowly over the next minute. Although 
blood pressure responses to SP in SHR and WKY rats were 
considerably different, no differences were seen in the 
effect of SP on RSNA in control SHR and WKY rats. This can
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best be explained by the fact that renal nerve activity is 
consistently and profoundly influenced by the magnitude of 
baroreceptor discharge. Since SP affects mean arterial 
pressure and thus baroreceptor activity, RSNA responses to 
SP in control rats are presumably "baroreceptor biased".
The finding that baroreceptor activation precludes 
direct measurement of RSNA responses to SP prompted the 
testing of several techniques to eliminate baroreceptor 
input. Following ganglion blockade with 20 /mol/kg 
chlorisondamine, RSNA responses to SP were slightly greater 
in SHR than WKY rats. However, owing to high variability in 
the response this was statistically significant at only one 
dose. It is likely that this is due to excessive lowering 
of blood pressure following ganglion blockade, resulting in 
deterioration of the preparation. Subsequent experiments 
demonstrated that blood pressures were better maintained 
when rats were artificially ventilated.
CD rats were subsequently used to evaluate various 
other treatments designed to eliminate baroreceptor input 
during ganglion stimulation. In these experiments the 
ganglion stimulant DMPP was used owing to the fact that in 
control rats, RSNA responses to DMPP demonstrated marked 
baroreceptor-mediated inhibition. The response involves a 
brief (2-5 sec) but intense burst of activity followed by a 
long-lasting (1-2 min) inhibition of RSNA. The inhibitory 
response was confirmed to be baroreceptor mediated since it 
was eliminated following sinoaortic denervation or pithing,
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or by a-adrenoceptor blockade with 30 jimol/kg 
phenoxybenzamine. After evaluation of the various 
techniques for eliminating baroreceptor input, sinoaortic 
denervation was chosen on the basis of its effectiveness and 
selectivity.
Cardiovascular effects of DMPP after adrenoceptor 
blockade were complex. Pressor and tachycardic effects of 
DMPP were attenuated but not eliminated by blockade of both 
a- and B-adrenoceptors with phenoxybenzamine and 
propranolol. The pressor effect of DMPP remaining after 
adrenoceptor blockade may be due to increased cardiac 
output. Another possibility is that ganglion stimulation 
causes the release of a nonadrenergic vasoconstrictor whose 
pressor effect is revealed only after blockade of vascular 
B2~adrenoceptors. Since sympathetic cardiovascular 
terminals are particularly rich in the vasoconstrictor 
neuropeptide Y (NPY) (Lundberg et al., 1982), this peptide 
may participate in the pressor response observed following 
ganglion stimulation. Agonist/antagonist competition at 
cardiac B-adrenoceptors may explain the tachycardia 
produced by DMPP after 5 ol/kg propranolol.
It should be noted that since the increase in blood 
pressure caused by DMPP was sustained even though RSNA was 
decreased, changes in renal nerve activity produced by 
ganglion stimulants are not always accompanied by 
corresponding changes in blood pressure. This may be 
explained by overflow of neurally-released catecholamines
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into the plasma. In fact, sympathetic activity is often 
evaluated by measuring changes in the level of plasma 
catecholamines. Since blood pressure was also maintained 
above baseline for 1-2 minutes following NE injection (see 
figure 16), a sustained increase in plasma epinephrine 
and/or norepinephrine probably accounts for the long-lasting 
elevation in blood pressure following injection of DMPP. In 
this way, blood pressure may remain elevated after ganglion 
stimulation has ceased.
Prior to sinoaortic denervation, renal nerve discharges 
in SHE were greater in both frequency and amplitude compared 
to WKY rats, consistent with the literature (Ekas and 
Lokhandwala, 1981). This elevation of intrinsic RSNA in SHR 
is best described as a change in the pattern and size of 
bursts of nerve activity. Discharges of renal sympathetic 
nerves were synchronized with pulse pressure in both SHR and 
WKY rats, with "bursts” of activity occurring most often 
during diastole. The frequency of these bursts was greater 
in SHR due to their occurrence during a greater percentage 
of cardiac cycles. Nerve recordings from SHR exhibited 
action potentials during diastole in 80-90% of cardiac 
cycles, sometimes continuing to fire over the course of 2-3 
cycles. In contrast, recordings from WKY rats often 
displayed bursts during only about 50% of cardiac cycles.
In addition, peak nerve discharges were usually slightly 
larger (about 200 pV) in SHR compared to WKY rats (about 150 
/iV). This difference between the pattern of discharge in
renal nerve recordings from SHR and WKY rats may be due to 
an attenuation of baroreceptor-mediated inhibition of RSNA 
in SHR, indicated by the fact that sinoaortic denervation 
enhanced intrinsic RSNA more in WKY than SHR by eliminating 
pulse-synchronous activity. Following sinoaortic 
denervation renal nerve recordings from both SHR and WKY 
rats exhibited continuous asynchronous discharge. These 
types of differences in pre- and post-denervation nerve 
activity are in agreement with electrophysiological evidence 
that tonic discharge of arterial baroreceptors is decreased 
in SHR (Brown et al., 1976).
As in the case of responses to DMPP, increases in RSNA 
following injection of SP were profoundly enhanced by 
sinoaortic denervation, confirming suspicions that 
baroreceptor influences on renal nerve activity during 
ganglion stimulation by SP are significant. Baroreceptor 
denervated SHR exhibited an elevated RSNA response to SP 
compared to WKY rats when nerve activity is expressed as a 
percent of the pre-drug baseline. This same increase was 
not observed for RSNA responses to DMPP, indicating that a 
selective enhancement of ganglion sensitivity to SP occurs 
in the SHR. in light of these data, it seems likely that 
differences in the ability of SP to increase blood pressure 
in SHR and WKY rats are due to a combination of two factors. 
As previously noted, SP causes less vasodilation in SHR than 
WKY rats, allowing for a greater effect of vasoconstrictor 
influences. In addition, a greater sympathetic discharge to
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the vasculature occurs In SHR compared to WKY rats after 
injection of SP resulting in greater a-adrenoceptor 
stimulation and thus enhanced vasoconstriction. The 
combination of these two factors is probably responsible for 
the consistent differences observed in blood pressure 
responses to SP in SHR and WKY rats.
The results of this study demonstrate that in SHR there 
is an increase in basal and evoked sympathetic tone. 
Elevation in basal sympathetic tone may be due to decreased 
baroreceptor-mediated inhibition of sympathetic outflow in 
SHR. This is indicated by observations that denervation of 
baroreceptors enhanced sympathetic tone more in WKY rats 
than in SHR. In addition, discharges in renal nerves which 
persisted after ganglion blockade were observed. These 
potentials are presumed to be generated peripherally, and 
may be due to release of SP in sympathetic ganglia, since 
this residual activity was greater in SHR than WKY rats, it 
is possible that an increased action of SP may also 
contribute to elevations in basal sympathetic outflow in 
SHR.
A selective increase in renal nerve responses to 
ganglion stimulation by substance P was observed. This was 
not also observed in response to ganglion nicotinic receptor 
stimulation by DMPP. Thus, SP may be responsible, at least 
in part, for the increased excitability of sympathetic 
ganglia in SHR. This effect of SP may in turn play a role 
in the increase in evoked sympathetic responses in SHR.
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It is unknown why the sympathostimulatory effects of SP 
are enhanced in SHR. One possibility is that it is merely a 
hereditary trait of SHR. Genetic programming may result in 
a different pattern of sensory innervation in sympathetic 
ganglia of SHR versus WKY rats. However, if peripheral 
modulation of sympathetic tone by SP is subject to reflex 
control by activation of sensory nerve terminals in the 
vasculature, then vascular alterations may disrupt this 
reflex. Thus, there may be a connection between the 
observed decrease in vasodilator effect and enhanced 
sympathetic responses to SP in SHR.
In conclusion, it appears that a selective increase in 
the action of SP to enhance neurotransmission in sympathetic 
ganglia is exhibited in SHR compared to WKY rats which may 
contribute to an elevation in basal and evoked sympathetic 
tone. This may result from changes in the vasculature which 
affect sensory regulation of vasomotor tone and contribute 
to elevations in blood pressure. Future studies utilizing 
non-genetic models of hypertension may help to increase 
understanding of the precise role that SP plays in the 
development of hypertension. Measurements of cardiovascular 
and sympathetic responses to substance P in models of 
hypertension such as the DOCA-salt (deoxycorticosterone 
acetate) rat may provide a clue as to whether or not changes 
in responsiveness to SP observed in SHR are genetically 
programmed or are the result of physiological adaptations to 
high blood pressure.
CHAPTER 5 
Summary
Results of the present study demonstrated the following:
1. Following intravenous injection of substance P, SHR
exhibit a dose-dependent increase in blood pressure and
heart rate which is significantly greater than that 
observed in normotensive WKY rats.
2. Increases in blood pressure and heart rate due to
substance P are accompanied by an increase in renal
sympathetic nerve activity (RSNA) which persists after 
ganglion blockade or pithing.
3. Baroreceptor mediated inhibition of RSNA significantly 
depresses responses to sympathetic ganglion stimulation 
by both substance P and the nicotinic agonist DMPP.
4. SHR exhibit greater intrinsic sympathetic tone and less 
enhancement of RSNA following baroreceptor denervation 
than WKY rats.
5. After adrenoceptor blockade, only depressor responses 
to substance P are exhibited. These responses are 
attenuated in SHR compared to WKY rats.
6. After sinoaortic denervation, SHR exhibit an enhanced 
RSNA response to ganglion stimulation by substance P 
versus WKY rats.
7. Enhanced cardiovascular and sympathetic responses to 
substance P in SHR rats are not the result of 
generalized increases in ganglion or adrenoceptor 
sensitivity.
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